HSP90AA1 and PDE4B are two promising druggable targets as single or combined administration of the inhibitor of HSP90AA1 or PDE4B that markedly reduced the proliferation and increased the apoptosis in ESCC cells [8]. The gene discussed is PDE4B; the disease is esophageal squamous cell carcinoma.